Chase Investment Counsel’s Amedisys AMED Stock Holding History

Chase Investment Counsel’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-935	Closed	-$274K	–	101
2020 Q4	$274K	Hold	935	–	–	0.12%	93
2020 Q3	$221K	Buy	+935	New	+$213K	0.11%	90
2017 Q3	–	Sell	-8,270	Closed	-$519K	–	86
2017 Q2	$519K	Buy	+8,270	New	+$482K	0.25%	67

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Chase Investment Counsel's AMED Position: Q1 2021 in Review

Chase Investment Counsel sold out of Amedisys (AMED) in Q1 2021, closing a stake of 935 shares — an estimated $274K sold.

Chase Investment Counsel first reported a position in AMED in Q2 2017 and held it in 3 quarters. The position peaked at $519K in Q2 2017. 388 funds tracked by Wall St. Rank hold AMED as of Q1 2021.

Chase Investment Counsel reported no remaining Amedisys position as of Q1 2021 after selling out during the quarter.
Chase Investment Counsel sold 935 Amedisys shares in Q1 2021, an estimated $274K.
Chase Investment Counsel first reported a position in Amedisys in Q2 2017 and held it in 3 quarters.
Chase Investment Counsel's Amedisys position peaked at $519K in Q2 2017.
388 funds tracked by Wall St. Rank held Amedisys as of Q1 2021.

Based on Chase Investment Counsel's 13F filing for Q1 2021, filed 6 May 2021.